Abstract
Previous antithrombotic research has centered around the search for antiplatelet drugs that could inhibit aggregation in response to all agonists. To date, only agents that elevate cyclic AMP such as PGI2 met the above criterion. In this report we discuss the discovery of a new class of antiplatelet compounds (2-aminochromones) that inhibit aggregation induced by all agonists without elevating cyclic AMP. 2- aminochromones are potent platelet phospholipase C (PLC) inhibitors. These data suggest that PLC activation is a central controlling activity of agonist-stimulated platelet aggregation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benjamin, C.W., Connor, J.A., Tarpley, W.G. and Gorman R.R. Proc. Nat. Acad. Sci. USA 85:4345–4349, 1988.
Johnson, P.C., Ware, J.A., and Salzman, E.W. Th.rombosis Research 40:435–443, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Benjamin, C.W. et al. (1993). Inhibition of Human Platelet Aggregation by Novel 2-Aminochromone Phospholipase C Inhibitors. In: Nigam, S., Honn, K.V., Marnett, L.J., Walden, T.L. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Developments in Oncology, vol 71. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3520-1_45
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3520-1_45
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6562-4
Online ISBN: 978-1-4615-3520-1
eBook Packages: Springer Book Archive